RxDoctor Payments Data

Katherine Wong, MD

Neurology · Los Angeles, CANPI 1750735767

Payments from drug & device makers

$32,273in general payments, 2019–2025

Across 81 payments — averaging $398.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$20K
  • Medtronic$8K
  • Abbott$4K
  • Teva Pharmaceuticals USA, Inc.$145
  • Acorda Therapeutics, Inc$135
  • Gilead$118
  • plus $175 from 4 others

What the payments were for

  • Consulting fees$4501%
  • Grants$24,25075%
  • Travel & lodging$5,33217%
  • Food & beverage$2,1747%
  • Education$670%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Boston Scientific14$19,683
Medtronic31$8,462
Abbott19$3,555
Teva Pharmaceuticals USA, Inc.2$145
Acorda Therapeutics, Inc1$135
Gilead6$118
AbbVie3$70
Amneal Pharmaceuticals LLC3$47
Neurocrine Biosciences, Inc.1$35
Cipher Pharmaceuticals US LLC1$23

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$32,273 in reported general payments places this provider in the 80th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$42,136
Medicare patients
149
Services billed
350

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RytaryCarbidopa/Levodopa36$66,571
GocovriAmantadine Hcl11$23,381
Carbidopa-LevodopaCarbidopa/Levodopa128$6,807
Carbidopa-Levodopa ErCarbidopa/Levodopa91$3,879
Entacapone18$2,384
AmantadineAmantadine Hcl22$2,190
Donepezil Hcl95$1,427
Memantine Hcl22$703
Escitalopram Oxalate72$597
Quetiapine Fumarate47$522
Celecoxib13$507
Primidone16$371
Clonazepam34$275
Gabapentin26$213
Trazodone Hcl41$162

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Amneal Pharmaceuticals LLCRytary$47$66,57136 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,996 neurology providers in California.

Other neurology in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →